Global Travel Vaccine Market, By Composition (Mono Vaccines, Combination Vaccines), Disease (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others)– Industry Trends and Forecast to 2029.
Travel Vaccine Market Analysis and Size
A biological preparation known as a vaccination offers active acquired protection to a specific infectious disease. A vaccination often comprises a substance that resembles a germ that causes a disease, this substance is frequently created from a bacteria's weaker or dead forms, its toxins, or one of its surface proteins.
Data Bridge Market Research analyses that the travel vaccine market which was USD 3.2 billion in 2021, would rocket up to USD 7.70 billion by 2029, and is expected to undergo a CAGR of 11.6% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Travel Vaccine Market Scope and Segmentation
Report Metric |
Details |
Forecast Period |
2022 to 2029 |
Base Year |
2021 |
Historic Years |
2020 (Customizable to 2014 - 2019) |
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
Segments Covered |
Composition (Mono Vaccines, Combination Vaccines), Disease (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others) |
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
Market Players Covered |
GSK plc (U.K.), Sanofi (France), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Bavarian Nordic (Denmark), Janssen Pharmaceuticals Inc. (U.S.), CSL Limited (Australia), AstraZeneca (U.K.), Altimmune (U.K.), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Crucell (Netherlands) |
Market Opportunities |
|
Market Definition
Travel vaccinations, commonly referred to go vaccines, are shots that people can have before they travel to specific parts of the world to help prevent them from deadly infections. Travel vaccinations function by exposing the body to a bacterium or specific components of the pathogen that causes the sickness they are intended to prevent.
Travel Vaccine Market Dynamics
Drivers
- Increase in cases of flu
The flu part for the most comprehensive travel vaccine business serving is estimated based on the target virus. That was largely attributable to the enormous number of cases of influenza that were accounted for throughout the forecast period and the segment will continue to control the market.
- Increase in costs for vaccination
Travel-related viruses like hepatitis, tetanus, Japanese encephalitis, meningitis, and yellow fever are becoming more widespread all over the world. This would significantly increase the costs associated with the development of more effective vaccinations, opening up new market opportunities for travel vaccines throughout the forecast period of 2022 to 2029.
- Rising number of vaccines
Global arrivals of foreign visitors surged from 1.0 billion in 2012 to about 1.4 billion in 2018. Many of these tourists travel from rich nations to places where endemic diseases are prevalent. The need for vaccines will rise as more individuals travel to nations where certain diseases are widespread.
Opportunities
In the evolution of infections, more human contact with various invertebrates and plants has also emerged. This helps vaccine businesses finance research and development initiatives to create fresh, improved, and effective vaccines that will increase the market's expansion potential.
Restraints/Challenges
Due to some market limitations, it can be difficult to stock travel vaccines at an ambiguous temperature. Certain room conditions are necessary for vaccinations. There are many different medical histories. Resuming the vaccination schedule after puberty may have additional negative effects.
This travel vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the travel vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Travel Vaccine Market
Regulations and advice relating to travel vaccines mostly addressed infectious diseases prior to the COVID-19 pandemic of 2020. However, they revealed a discrepancy among travellers, with some choosing not to get immunised owing to cost, lack of knowledge, and personal preference. Examples of this include travellers visiting friends and relatives and casual travellers. Numerous endemics and international illnesses resulted from this. The COVID-19 epidemic has substantially impacted the world's health economies and put enormous pressure on the global travel vaccine market.
Global Travel Vaccine Market Scope
The travel vaccine market is segmented on the basis of composition and disease. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Composition
- Mono Vaccines
- Combination Vaccines
Disease
- Hepatitis A
- DPT
- Yellow Fever
- Typhoid
- Hepatitis B
- Measles and Mumps
- Rabies
- Meningococcal
- Varicella
- Japanese Encephalitis
- Others
Travel Vaccine Market Regional Analysis/Insights
The travel vaccine market is analysed and market size insights and trends are provided by country, composition and disease as referenced above.
The countries covered in the travel vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominate the travel vaccine market due to the constant updates on traveling safety, crises, epidemic brawls, and concerns associated with vaccine stocks in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people and growing demand of advanced vaccines.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Travel Vaccine Market Share Analysis
The travel vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to travel vaccine market.
Some of the major players operating in the travel vaccine market are:
- GSK plc (U.K.)
- Sanofi (France)
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Bavarian Nordic (Denmark)
- Janssen Pharmaceuticals Inc. (U.S.)
- CSL Limited (Australia)
- AstraZeneca (U.K.)
- Altimmune (U.K.)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Crucell (Netherlands)
SKU-